Sign in
Taking peopleEarly phase 1

LY-M003 gene therapy injection for people with Wilson disease

Tests LY-M003, a gene therapy given once, in people with Wilson disease.

Key facts

Who runs it
Chaohui Yu
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
A Clinical Study to Evaluate the Safety and Efficacy of LY-M003 Injection in Patients With Wilson Disease
Status
Recruiting
Phase
Early phase 1
People taking part
18 people, planned
Started
24 Sept 2024
Expected to end
30 Mar 2030
Type of study
Interventional, 5 groups
Treatments tested
  • LY-M003
Record updated
23 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 10 to 60 with Wilson disease who have already had standard treatment. Everyone gets one infusion of the gene therapy LY-M003 into a vein.

Age
10 Years to 60 Years
Sex
All sexes
Disease stage
Wilson disease. People with decompensated cirrhosis or advanced liver disease cannot join. The MELD liver score must not be above 13.
Earlier treatment
Standard treatment for Wilson disease (for example D-penicillamine or zinc acetate) for at least 6 months before screening. A low-copper diet for at least 6 months before screening. No earlier gene therapy or cell therapy of any kind.
Biomarker or test result
Lab tests must show changes in both copies of the ATP7B gene. AAV8 neutralizing antibody titer must not be above 1:10.

Main reasons for not taking part

  • Decompensated cirrhosis or advanced liver disease, or other liver diseases
  • Active bleeding in the gut within the past 3 months
  • Past or planned organ, bone marrow or stem cell transplant
  • Kidney disease on dialysis or creatinine clearance < 60 mL/min
  • Pregnant or breastfeeding, or planning a pregnancy

The registry criteria, word for word

Show all 34 criteriaShow less

Who can take part

  • The subject must be able to fully understood the purpose, nature, method, and possible adverse effects of the study, must be able to voluntarily participate in the study and voluntarily able to provide the written informed consent form (ICF)
  • Patients diagnosed with Wilson Disease
  • Wilson Disease (WD) patients confirmed by laboratory tests to have biallelic mutations in the ATP7B gene
  • Subjects must be treatment-experienced to WD who have received standard treatment (eg, D-penicillamine or zinc acetate) for at least 6 months prior to the screening period
  • Subjects must restrict food with high copper content for at least 6 months prior to screening and continue this restriction during the entire duration of study participation
  • Subjects must be willing to refrain from donating blood, organs, tissues or cells during study participation
  • Negative pregnancy test in women of childbearing potential (WOCBP)
  • Subjects and their partners who have no childbearing plans from the screening period to 6 months after the end of the study and are willing to adopt effective contraceptive measures (e.g., abstinence, condoms, etc.); subjects have no plans to donate sperm or ova

Who cannot take part

  • AAV8 neutralizing antibody titer > 1:10
  • History of noncompliance with copper chelators or zinc agents within 6 months prior to screening, as determined by the investigator
  • A history of epileptic seizures or other diseases that may potentially affect compliance with study procedures within 6 months prior to the screening period
  • Subject received or plans to receive bone marrow transplantation, hematopoietic stem cell transplantation and/or major organ transplantation, including but not limited to liver transplantation, kidney transplantation, etc
  • Patients with uncontrolled concomitant diseases or infectious diseases as judged by the investigator
  • Subjects who have previously received gene therapy or cell therapy of any kind
  • Subjects who use systemic immunosuppressive agents or receive steroid therapy within 3 months prior to dosing (except for prophylactic immunosuppressive therapy as specified in protocol)
  • Subjects who have vaccinated with attenuated live vaccine within 4 months prior to screening or plan to receive a live attenuated vaccine during the clinical trial
  • Subjects who have received treatment or disposition with another investigational drug or investigational device within 28 days or 5 half-lives (drug only), whichever is longer, prior to screening
  • Active gastrointestinal bleeding within the past 3 months
  • Decompensated cirrhosis or advanced hepatic disease, manifested as portal hypertension, ascites, splenomegaly, esophageal varices, hepatic encephalopathy, etc
  • Subjects with other liver diseases as determined by the investigator, such as immune hepatitis, alcoholic liver disease, primary biliary cholangitis, primary sclerosing cholangitis, and/or drug or toxic liver disease
  • Model for End-Stage Liver Disease (MELD) Score > 13
  • Other disorders of copper metabolism, such as chronic cholestatic liver diseases, disorders of glycosylation, copper metabolism disorders, etc
  • Hepatitis B surface antigen (HBsAg) positive, hepatitis C virus (HCV) antibody positive, human immunodeficiency virus (HIV) antibody positive or Treponema pallidum antibody positive
  • Clinically diagnosed or judged as serious cardiovascular disease by the investigator (eg, classification of heart failure ≥ 3 according to New York Heart Association [NYHA])
  • Subjects who have hypersensitivity to any component of LY-M003 injection
  • Subjects with history of cancer within 5 years prior to screening, except for completely resected non-melanoma skin cancer, non-metastatic prostate cancer and completely cured ductal carcinoma in situ
  • Subjects with treatment-experienced WD who have ALT and/or AST 5 times greater than the upper limit of normal (ULN)
  • Hemoglobin < 90 g/L
  • Subjects with end-stage renal disease receiving dialysis (chronic kidney disease stage 3 and above) or creatinine clearance < 60 mL/min
  • Severe hyperlipidemia (triglycerides > 1000 mg/dL)
  • Subjects considered as complicated with severe hypersplenism and requiring splenectomy as judged by the investigator
  • Severe central nervous system symptoms urgent for intensive hospitalization judged by the investigator
  • Pregnant women (or women planning to become pregnant) or lactating women
  • Other circumstances in which the investigator deems the subject inappropriate for study participation

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 10 and 60 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Wilson's disease (WD), also known as Wilson's disease, is a rare autosomal recessive metabolic disorder caused by a mutation of the copper transport ATPase β (ATP7B) gene located on the long arm of chromosome 13 (13q14.3). This leads to accumulation of copper ions in multiple organs such as liver, brain and kidney, resulting in organ involvement. In this study, LY-M003 Injection is a gene therapy products with rAAV8 vector. After a single intravenous infusion, LY-M003 can be transduced to the target organ of liver and express the ATP7B in hepatocytese.

The 5 groups in the trial

  • LY-M003 Dose group 1-Adult CohortTreatment being tested

    Adult participants receive a single, peripheral intravenous (IV) infusion of LY-M003 at dose group 1.

    Treatment: LY-M003

  • LY-M003 Dose group 2-Adult CohortTreatment being tested

    Adult participants receive a single, peripheral intravenous (IV) infusion of LY-M003 at dose group 2.

    Treatment: LY-M003

  • LY-M003 Dose group 3-Adult CohortTreatment being tested

    Adult participants receive a single, peripheral intravenous (IV) infusion of LY-M003 at dose group 3.

    Treatment: LY-M003

  • LY-M003 Dose group 4-Adult CohortTreatment being tested

    Adult participants receive a single, peripheral intravenous (IV) infusion of LY-M003 at dose group 4.

    Treatment: LY-M003

  • LY-M003-Pediatric CohortTreatment being tested

    Based on the accumulated efficacy and safety data of enrolled adult subjects, the investigator and collaborators will determine the starting dose, subsequent enrollment doses for pediatric participants.

    Treatment: LY-M003

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prospective, Single-center, Open-label, Single-arm, Single-dose Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult and Pediatric Patients With Wilson Disease
Plain-language title
LY-M003 gene therapy injection for people with Wilson diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06650319, who can take part
Record updated
23 January 2026